Rongchang Biotech (09995) and Vor Bio sign a revised license agreement

According to Zhitong Finance App News, Rongchang Biotech (09995) announced that in order to further enrich the product portfolio of the two parties in the field of global autoimmunity under the license agreement and accelerate the international development of the company's innovation pipeline, on November 12, 2026, the company and Vor Bio signed a revised agreement (revised agreement) on the license agreement to include the company's RC298 (licensed product) with independent intellectual property rights within the scope of cooperation. Vor Bio will be distributed globally (i.e., mainland China, Hong Kong, Macau and Taiwan)) ( (License area) Exclusive right to develop and commercialize RC298.

According to the terms of the revised agreement, the Company will receive a total down payment of approximately 56 million US dollars from Vor Bio, including a cash down payment of 10 million US dollars and a share warrant worth approximately 46 million US dollars (calculated based on the closing stock price of Vor Bio shares on November 11, 2026) to subscribe for 2.3 million shares of Vor Bio common shares at an exercise price of $0.0001 per share. Under the revised agreement, the company is also eligible for development milestone payments of up to $300 million, of which $20 million will be received after reaching early clinical development and technology transfer milestones. The sales milestones and royalty mechanisms under existing license agreements will continue to apply and will be calculated based on the combined sales of all licensed products. Milestone payments agreed in the revised agreement are subject to certain conditions, and there is still uncertainty about the amount of milestone payments that the Company can ultimately achieve.

The revised agreement and proposed transactions under it will help RC298 develop the market in the licensed region, provide innovative treatment solutions for patients with autoimmune diseases around the world, and further enhance the company's brand value and international influence. Through such transactions, the Company can obtain down payments, milestone payments and sales commissions to enhance the company's cash flow while diversifying overseas clinical research and development risks.